Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Semax is a synthetic heptapeptide that appears frequently in preclinical neuropeptide research. Its sequence is modeled on the ACTH(4-7) region of adrenocorticotropic hormone and extended at the carboxyl terminus with a proline-glycine-proline (Pro-Gly-Pro) motif that slows enzymatic breakdown. This structure places Semax within the family of melanocortin-derived peptides, although laboratory characterizations describe it as largely uncoupled from the classical corticotropic (hormone-releasing) activity of the parent molecule. In research settings, the peptide is studied for how it interacts with neurotrophic signaling rather than endocrine output.
Investigative interest in Semax organizes around two studied themes: cognition-related signaling and neuroprotection. Across animal and in-vitro work, researchers have examined its relationship to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and downstream pathways tied to hippocampal plasticity. The sections below outline how these targets are framed within preclinical cognition and neuroprotection models. Nothing here characterizes human application: this material is provided for research use only, not for human consumption, and every observation described derives from controlled laboratory systems.
Molecular Identity and Structural Design
Understanding how Semax is studied begins with its molecular architecture, because the peptide’s stability and target interactions both trace back to its short sequence.
Sequence and Peptide Class
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to a fragment of adrenocorticotropic hormone, which is why the compound is often classified as a synthetic ACTH(4-10) analog. Its reported molecular weight sits near 813.9 g/mol, and the molecular formula is commonly listed as C37H51N9O10S. Because it lacks the full ACTH structure, research characterizations emphasize its neuromodulatory profile over any hormone-releasing role.
Why the Pro-Gly-Pro Tail Matters
The terminal Pro-Gly-Pro sequence is a deliberate design feature. Proline-rich terminals resist cleavage by aminopeptidases and carboxypeptidases, which extends the functional window of the peptide in experimental systems. This relative metabolic stability is one reason Semax is a practical tool compound in preclinical work, where consistent exposure across an experiment is valued. Suppliers typically document identity and purity on a certificate of analysis; the basics of interpreting those documents are covered in this COA and purity guide, and batch certificates are published for reference.
The following values reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported Value |
|---|---|
| Peptide class | Synthetic ACTH(4-10) analog (melanocortin-derived) |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Sequence length | 7 residues (heptapeptide) |
| Approximate molecular weight | 813.9 g/mol |
| Molecular formula | C37H51N9O10S |
| Primary studied targets | BDNF and NGF neurotrophin signaling |
| Research category | Nootropic and neuroprotective peptide (preclinical) |
Neurotrophic Signaling in Cognition Models
The most studied dimension of Semax research concerns neurotrophins, the growth factors that support neuron survival, differentiation, and synaptic remodeling.
BDNF and the TrkB Pathway
In rodent studies, investigators have reported associations between Semax exposure and changes in BDNF expression within the hippocampus, a region central to learning and memory research. BDNF signals through the TrkB receptor, and preclinical work has examined whether Semax influences this axis at the level of messenger RNA and protein. These are mechanistic observations in animal and cell models, not statements about outcomes in people.
NGF and Cholinergic Circuits
Parallel research has looked at nerve growth factor (NGF), another neurotrophin, and its relationship to cholinergic neurons. Some rodent experiments describe shifts in NGF-related signaling following Semax administration in the laboratory, a pathway of interest because cholinergic circuits are frequently modeled in cognition studies. As with BDNF, these findings are confined to experimental systems.
Behavioral Paradigms in Animals
Beyond molecular readouts, Semax has been examined in behavioral paradigms used to model attention, learning, and memory consolidation in rodents, such as maze-based tasks and passive avoidance protocols. Researchers use these paradigms to probe how a compound interacts with cognition-related circuitry under controlled conditions. The results inform hypotheses about mechanism and do not translate into claims of benefit for humans.
Neuroprotection Research Models
The second major research theme places Semax in models designed to stress neural tissue, where investigators measure how the peptide correlates with markers of cell survival.
Cerebral Ischemia and Hypoxia Models
Experimental cerebral ischemia models, in which blood flow to brain tissue is transiently restricted in laboratory animals, are a common setting for Semax neuroprotection research. In these models, researchers quantify endpoints such as lesion size and neuronal counts to characterize how the peptide behaves under hypoxic stress. Findings are interpreted strictly within the model system and are not generalized to clinical settings.
Oxidative Stress and Inflammatory Markers
Because ischemic injury involves oxidative stress and inflammatory signaling, related studies track antioxidant enzyme activity and cytokine levels in treated versus control tissue. Semax has been profiled against these markers to map its position within the cascade of events that follow neural insult in preclinical designs.
Gene Expression Studies
Transcriptomic research adds another layer. Using microarray and related methods, investigators have catalogued how Semax exposure correlates with the expression of gene sets tied to neurotrophins, vascular signaling, and immune response in rodent brain tissue. This systems-level view helps researchers frame the peptide’s studied activity as a network effect rather than a single-target action.
Comparative Context Among Nootropic Peptides
Semax is often discussed alongside other regulatory peptides investigated in the nootropic and neuroprotection literature. Placing it in context clarifies what is distinctive about its studied profile.
Semax and Selank
Semax is frequently compared with Selank, a synthetic analog of the immunopeptide tuftsin. Both are short, proline-stabilized peptides developed within Russian neuropeptide research programs, yet their studied targets differ: Semax centers on melanocortin-derived and neurotrophic signaling, while Selank research emphasizes anxiolytic and immunomodulatory pathways. Researchers comparing sources for either compound may find this guide on choosing a research peptide supplier useful, and a full research peptide catalog is available for reference material.
The following values reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Semax | Selank |
|---|---|---|
| Sequence length | 7 residues | 7 residues |
| Approximate molecular weight | 813.9 g/mol | 751.9 g/mol |
| Parent molecule | ACTH(4-10) | Tuftsin |
| Peptide class | Melanocortin-derived analog | Immunomodulatory tuftsin analog |
| Primary research focus | Cognition and neuroprotection | Anxiolytic and immunomodulatory signaling |
Frequently Asked Questions
What is Semax and what is it studied for?
Semax is a synthetic heptapeptide derived from an ACTH fragment. In preclinical research it is studied for its interactions with neurotrophic signaling, including BDNF and NGF, and it appears in cognition and neuroprotection model systems. It is a laboratory research compound only.
What pathway does Semax act on in research models?
Studies focus on melanocortin-derived signaling and neurotrophin pathways, particularly BDNF signaling through the TrkB receptor and NGF-related activity in rodent brain tissue. These are mechanistic observations from animal and in-vitro work.
Is Semax an ACTH analog?
Yes. Semax is modeled on the ACTH(4-7) region of adrenocorticotropic hormone with an added Pro-Gly-Pro tail. Research characterizations describe it as largely separated from the hormone-releasing activity of full ACTH, which is why it is studied as a neuromodulatory peptide.
How does Semax relate to BDNF in preclinical studies?
Rodent studies have reported associations between Semax exposure and BDNF expression in the hippocampus, along with signaling through the TrkB receptor. These findings are limited to experimental models and do not describe effects in humans.
What neuroprotection models involve Semax?
Semax is commonly examined in experimental cerebral ischemia and hypoxia models, where researchers measure lesion size, neuronal survival, oxidative stress markers, and gene expression changes in laboratory animals.
Is Semax approved for human use?
No. Semax discussed here is a research compound intended for laboratory study. It is sold for research use only, not for human consumption, and nothing in this article should be read as guidance for human application.
References and Further Reading
- Institute of Molecular Genetics (Russian Academy of Sciences) and N.F. Myasoedov: foundational characterization of Semax as a synthetic ACTH(4-10) analog. PubMed: semax ACTH analog
- Preclinical research on Semax and brain-derived neurotrophic factor expression in rodent hippocampus. PubMed: semax BDNF
- Studies of Semax and nerve growth factor signaling in neural tissue. PubMed: semax nerve growth factor
- Animal models of cerebral ischemia used to investigate Semax neuroprotection. PubMed: semax cerebral ischemia
- Gene expression and transcriptomic studies of Semax in brain tissue. PubMed: semax gene expression
- Semax in cognition and learning research paradigms. PubMed: semax cognitive
- Overviews of melanocortin-derived neuropeptides and neuroprotection research. PubMed: semax neuroprotection
